Instruments to measure disease activity in systemic lupus erythematosus - Is our net tight enough to catch the hydra?

Journal of Rheumatology

Volumn 38, Issue 1, 2011, Pages 3-4

  Sturfelt, Gunnar ^a   Nived, Ola ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEW DRUG;

ALOPECIA; BRITISH ISLES LUPUS ASSESSMENT GROUP INDEX; CLINICAL ASSESSMENT TOOL; CLINICAL EDUCATION; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESEARCH; EDITORIAL; EUROPEAN CONSENSUS LUPUS ACTIVITY MEASURE; FOLLOW UP; HUMAN; INSTRUMENT; INTERSTITIAL CYSTITIS; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RASH; SYSTEMIC LUPUS ACTIVITY MEASURE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 78650915136     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.101024     Document Type: Editorial

References (7)

1. Isenberg DA, Horsfall A. Systemic lupus erythematosus: adult onset. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, editors. Oxford textbook of rheumatology. Oxford: Oxford University Press; 1993:733-55.
2. Ibañez D, Urowitz MB, Gladman DD. Disease activity over time (adjusted mean SLEDAI) predicts mortality and damage in SLE. J Rheumatol 2005;32:824-7.
3. Gladman DD, Ibañez D, Urowitz MB. SLE Disease Activity Index 2000. J Rheumatol 2002;29:288-91.
4. Yee CS, Farewell V, Isenberg D, Prabu A, Sokoll K, Teh LS, et al. Revised British Isles Lupus Assessment Group 2004 Index. A reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum 2006;54:3300-5.
5. Ibañez D, Gladman DD, Touma Z, Nikpour M, Urowitz MB. Optimal frequency of visits for patients with SLE to measure disease activity over time. J Rheumatol 2011;38:60-3.
6. Bruce IN. Re-evaluation of biologic therapies in systemic lupus erythematosus. Curr Opin Rheumatol 2010;22:273-7.
7. Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA. Non-renal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment of lupus nephritis. Arthritis Rheum 2010;62:211-21.